Medical Developments International (MVP) Investor update summary

Capital raise and financial discipline

• Announced a AUD 10 million capital raise to fund targeted growth initiatives and strengthen the balance sheet, aiming for operating cash flow positivity by end of FY25.

• AUD 6.5 million will be invested in growth plans, with AUD 3.5 million allocated to working capital and fees.

• Cost reductions, paused long-term investments, and a capital-light approach have improved margins and financial discipline.

• FY24 saw improved earnings by AUD 7 million, free cash flow by AUD 10 million, and a 3% revenue increase.

• Post-raise, cash reserves are expected to be around AUD 19 million, supporting growth initiatives and free cash flow positivity.

Product and market strategy

• Penthrox remains the lead product, with high loyalty and continued growth in both existing and new markets.

• Significant opportunity identified in emergency departments and procedural settings, especially in women's health.

• The MAGPIE pediatric study could expand the addressable market in Europe by lowering the age indication from 18 to 6 years.

• A revised strategy focuses on medical engagement over traditional sales, aiming to accelerate hospital adoption.

• International partnerships, especially in the UK and Nordics, have been extended on improved terms, reflecting confidence in growth potential.

Growth drivers and operational focus

• Targeting a revenue CAGR of up to 15% over five years, effectively doubling current revenues.

• Respiratory franchise has grown at 30%+ CAGR since FY21, with 80% growth in the US market.

• Continued focus on pricing aligned with product value, with market research indicating price is not a barrier to uptake.

• Field team efforts in Australia are shifting to a more cost-effective, medically driven engagement model.

• Evidence generation and knowledge exchange, including leveraging MAGPIE data, are key to supporting advocacy and uptake.